Cryo-trojan mesenchymal stem cells as non-living tumor-homing supercarriers for enhanced drug delivery and immune activation in prostate cancer.

ABSTRACT:

Background

Prostate cancer remains a leading cause of cancer-related mortality, with conventional therapies limited by systemic toxicity and poor tumor targeting. Developing innovative drug delivery systems that enhance therapeutic specificity while minimizing off-target effects is critical.

Materials and methods

We engineered cryo-trojan human umbilical cord mesenchymal stem cells (CT-MSCs) as non-living, tumor-homing carriers for mitoxantrone (MTX), termed CT-MTX. Cryo-treatment preserved structural integrity and chemokine receptors (CXCR4/CCR2) for tumor targeting while eliminating proliferative risks. Comprehensive evaluations included drug loading/release kinetics, in vitro tumor suppression, immunogenic cell death (ICD) induction, and in vivo efficacy/safety in

SUBMITTER: Wang C 

PROVIDER: S-EPMC11937679 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature